EMBL spin-off Epitome Therapeutics launches to advance precision epigenome editing

Epitome Therapeutics, a new EMBL spin-off, translates epigenome editing research into precision medicines. Co-founded by EMBL group leader Jamie Hackett, the company builds on pioneering research from EMBL Rome to open new possibilities for treating diseases caused by dysregulated gene expression.

24 July 2026